← Human Trials & Peer-Reviewed Studies
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Plain-language guide to PMID 33755728 (2021): double-blind randomized controlled trial study of Semaglutide in 2020 adults, fat loss, obesity & body recomposition.
Key Facts
- PMID
- 33755728
- Journal
- JAMA
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Rubino D et al. (14 authors)
- DOI
- 10.1001/jama.2021.3224
- Registered trial
- NCT03548987
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Semaglutide in the context of fat loss, obesity & body recomposition.
The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown.
Who Took Part
The study group was 2020 adults.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites in 10 countries from June 2018 to March 2020 in adults with body mass index of at least 30 (or ≥27 with ≥1 weight-related comorbidity) and without diabetes.
A total of 902 participants received once-weekly subcutaneous semaglutide during run-in.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The adults were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.
Some adults received a placebo instead of Semaglutide, giving a reference point.
What Was Measured
Topics PubMed links to this paper include Anti-Obesity Agents, Blood Pressure, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Obesity, Overweight and Waist Circumference.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 2020 adults in people with fat loss, obesity & body recomposition.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (JAMA), a journal based in United States.
More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.